Chemotherapy or radio-chemotherapy for advanced adenocarcinoma of the oesophagus and cardia;Adénocarcinomes du bas œsophage et du cardia: Quelle chimiothérapie ou chimioradiothérapie dans le traitement des récidives et des métastases?

Cancer/Radiotherapie

Volumn 5, Issue SUPPL. 1, 2001, Pages

  Seitz, J F ^a   Duffaud, F ^a   Dahan, L ^a   Ries, P ^a   Ville, E ^a   Laugier, R ^a  

^a Service d'Hepatogastroenterologie   (France)

Author keywords

Adenocarcinoma; Cardia; Chemoradiation; Chemotherapy; Esophagus

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARDIA CARCINOMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGUS CARCINOMA; FRANCE; HUMAN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIA; CISPLATIN; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MITOMYCIN; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035672184     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Multinational randomised trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC)
2. Progress report of combined chemo-radiotherapy versus radiotherapy alone in patients with oesophageal cancer. An intergroup study
3. A prospective study of combined therapy in esophageal cancer
4. Épidémiologie et pronostic des carcinomes gastriques dans le département du Calvados. Étude sur 10 ans
5. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
6. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
7. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of oesophageal carcinoma
8. Chemoradiotherapy of locally advanced oesophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01)
9. La prise en charge des cancers de l'œsophage differe-t'elle en fonction du type histologique?
10. A phase II trial of cisplatin and irinotecan in patients with advanced oesophageal cancer
11. Taxol and cisplatin + 5-fluorouracil sequential in advanced oesophageal cancer
12. Preoperative (neoadjuvant) chemo-radiotherapy in oesophageal cancer
13. Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy
14. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
15. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus
16. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the oesophagus
17. Chemotherapy followed by surgery compared with surgery alone for localized oesophageal cancer
18. Biweekly administration of cisplatin and increasing doses of paclitaxel in patients with advanced oesophageal cancer
19. A phase II study of paclitaxel, weekly 24-hour continuous infusion (CI) 5-fluorouracil, folinic acid (FA) and cisplatin in patients (pts) with advanced gastric cancer
20. Survival following intensive preoperative combined modality therapy with Paclitaxel, Cisplatin, 5FU and radiation in resectable oesophageal carcinoma
21. Prise en charge thérapeutique et survie de l'adénocarcinome gastrique dans le département du Finistère entre 1984 et 1989
22. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localised squamous cell carcinoma of the oesophagus
23. Phase II trial of oxaliplatin (OXA) in combination with 5FU and folinic acid (FA) - FOLFOX6 regimen - As first line treatment for advanced or metastatic gastric cancer (A/MGC) patients
24. Preoperative therapy with Paclitaxel, Carboplatin, 5FU and radiation in the treatment of local oesophageal cancer
25. Preliminary results of intergroup INT 0123 randomized trial of combined modality therapy for oesophageal cancer: Standard vs high dose radiation therapy
26. Chimiothérapie des cancers avancés de l'oesophage, du cardia et de l'estomac par l'association LV5FU2 + CDDP
27. Population-based study of diagnosis, treatment and prognosis of gastric cancer
28. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
29. Epidemology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent results in Cancer Research: Esophageal carcinoma
30. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer
31. Irinotecan (Iri) in combination with CDDP (C) or with 5-FU and folinic acid (FU/FA) is active in patients (pts) with advanced gastric or gastroesophageal junction adenocarcinoma (AGC)
32. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
33. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer
34. Docetaxel (Taxotere) -Cisplatin (TC): An effective drug combination in gastric carcinoma
35. Neoadjuvant chemotherapy in locally advanced gastric carcinoma. Phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum
36. Neoadjuvant Paclitaxel, Cisplatin and radiation therapy for oesophageal cancer
37. Concomitant chemoradiation therapy as palliative or neoadjuvant treatment of adenocarcinoma of the oesophagus and gastroesophageal junction
38. Alternatives au traitement chirurgical des adénocarcinomes de l'œsophage et du cardia
39. Radio-chimiothérapie concomitante dans les récidives des adénocarcinomes du cardia: Résultats d'un essai de phase II chez 16 patients
40. Standards, Options et Recommandations pour la prise en charge des patients atteints de cancer de l'œsophage
41. Récidives après traitement chirurgical des cancers épidennoïdes de l'œsophage-Approche thérapeutique chez 19 malades
42. Radio-chimiothérapie concomitante des cancers épidermoïdes de l'œsophage: Supériorité de la radiothérapie étalée sur la radiothérapie concentrée split-course. Résultats définitifs d'une étude nationale randomisée
43. Carcinoma of the gastroesophageal junction. Classification, pathology and extent of resection
44. A phase II trial of preoperative Cisplatin, Paclitaxel and radiation therapy before transhiatal oesophagectomy in patients with locoregional oesophageal cancer
45. Final results of a randomised phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer
46. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma
47. Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced oesophagogastric cancer